Six weeks after slapping a clinical hold on a trial of Ocugen’s COVID-19 vaccine, the FDA has lifted it. That’s the good news for the Malvern, Pa. company, which has partnered with India’s Bharat Biotech on the shot known commercially as Covaxin.
But the flip side for Ocugen is the declining demand for COVID vaccines in the United States. If Ocugen ever secures regulatory approval for Covaxin, will anyone want it—especially given the current surplus of available COVID jabs?
